Barclays Reiterates an 'Underweight' on Novo Nordisk (NVO); Shares Trading As If Not Risk Priced In

Article Stock Quotes (3) Comments (0)

Barclays reiterates an 'Underweight' on Novo Nordisk (NYSE: NVO).

Analyst, Brian Bourdot, said, "Novo Nordisk stock seems priced for flawless launch and growth of its new insulin degludec (Tresiba) for diabetes. We see near-term uncertainties in the form of physician unfamiliarity and a strong defence from Sanofi (NYSE: SNY). We see long-term risks from Lilly's (NYSE: LLY) LY2605541 and potentially other competitors, as well as a tougher pricing environment. We do not see these risks reflected in Novo's multiple of 20x 2013 earnings and reiterate our rating."

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $138.07 yesterday, with a 52 week range of $94.58-$152.31.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
• UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Barclays, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?